Trevi Therapeutics
TRVI· Manufacturing· Fiscal year ends in December
Jennifer Good is the CEO of Trevi Therapeutics and was paid $3.9M in FY2025 (Dec), up 52%.
Executives3
See all- 1Jennifer GoodPresident and Chief Executive OfficerFY2025
- 2James Cassella, Ph.D.Chief Development OfficerFY2025
- 3Farrell Simon, Pharm. D.Chief Commercial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTrevi Therapeutics paid its 3 named executives $6.9M in total in FY2025 (Dec). CEO Jennifer Good was paid $3.9M of that.
| Name | |||
|---|---|---|---|
| Jennifer GoodPresident and Chief Executive Officer | |||
| James Cassella, Ph.D.Chief Development Officer | |||
| Farrell Simon, Pharm. D.Chief Commercial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Trevi Therapeutics names 18 peer companies for pay. Among Trevi Therapeutics and these peers, CEO pay was 6th highest of 7 and total shareholder return was the highest of 7.
6th highest of 7in Trevi Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
1st highest of 7in Trevi Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 21, 2026 | FY2025 |
| Annual report | 10-K | Mar 17, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 18, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 20, 2024 | FY2023 |
